COMPARISON OF CHEMOTHERAPY REGIMENS IN CHILDREN WITH RHABDOMYOSARCOMA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究不再招募病人。 [摘自ClinicalTrials.gov网站(编辑)] 化疗中使用的药物以不同的方式阻止肿瘤细胞分裂，从而停止生长或死亡。联合使用多种药物可能会杀死更多的肿瘤细胞。 这是一项随机II期试验，旨在比较不同联合化疗方案对患有横纹肌肉瘤的儿童的疗效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is no longer recruiting patients. [from ClinicalTrials.gov website (edited)] Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. This is a randomized Phase II trial to compare the effectiveness of different combination chemotherapy regimens in treating children who have rhabdomyosarcoma.